ACUITY
- 13,800 participants
- 4 sites in New Zealand
- 600 sites globally
A randomised comparison of Angiomax® (bilvalirudin) versus heparin (enoxaparin or unfractionated heparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation. Randomisation is also designed to compare the timings of initiation of GPIIb/IIIa inhibitors in this population. This phase III global study is expected to be conducted at 600 sites in North America, Europe and Australasia with a total 13,800 patients followed up for 1 year.